Skip to main content
A stack of medical records on a desk beside a folio, glasses, and a pen.
Expert WitnessEUSAdvanced Endoscopy

LAMS Complications: What Attorneys Should Know When Reviewing an EUS-Guided Drainage Case

Dr. Kalpit Devani, MD, FACP, FACG, FASGE•Published October 31, 2026•Updated November 1, 2026•10 min read

What LAMS are and why the right reviewer matters

Lumen-apposing metal stents (LAMS) are short, wide, fully covered metal stents with a flange on each end. Under endoscopic ultrasound (EUS) guidance, the stent is placed across two structures that sit next to each other, such as the stomach and a fluid collection, or the duodenum and the bile duct. The flanges hold the two walls together and create a new passage. LAMS are sold under brand names that include Axios and Spaxus.

These procedures often take the place of an operation or a percutaneous drain. Their use has grown quickly since the first U.S. approval in 2013. When LAMS complications come up for medical malpractice review, the review needs attention to the specific procedure, the patient population, the technical circumstances, and the care that followed.

LAMS procedures are still a narrow field. They are done mostly by interventional endoscopists at referral centers. Reviewing these cases draws on hands-on experience with the devices, the anatomy, how adverse events show up in real time, and the rescue options. For an attorney or claims professional, that makes the choice of reviewing expert important from the first call.

Where LAMS are used

Each use carries its own anatomy, patient population, and risk profile. A review that treats them as one procedure can miss the point.

ProcedureWhat it doesTypical patient
Pancreatic fluid collection drainageDrains a pseudocyst or walled-off necrosis into the stomach or duodenumPatient recovering from severe pancreatitis
EUS-guided gallbladder drainage (EUS-GBD)Drains an inflamed gallbladder into the stomach or duodenumPatient with acute cholecystitis who is a poor surgical candidate
EUS-guided choledochoduodenostomy (EUS-CDS)Drains a blocked bile duct into the duodenumPatient with malignant biliary obstruction when ERCP has failed or is not possible
EUS-guided gastroenterostomy (EUS-GE)Creates a bypass from the stomach to the small bowelPatient with gastric outlet obstruction, often from cancer
EUS-directed transgastric ERCP (EDGE)Creates temporary access to the excluded stomachPatient with Roux-en-Y gastric bypass who needs ERCP

On-label and off-label uses of LAMS

LAMS were first designed for pancreatic fluid collections. Several of the uses above developed later, often outside the device's original labeling. A 2021 technology review in Gastrointestinal Endoscopy described off-label uses at that time, including gallbladder drainage, gastroenterostomy, and treatment of GI strictures (Gastrointest Endosc, 2021). A 2023 review listed EUS-GE, EUS-CDS, and EDGE among common off-label uses (Ann Med, 2023). Short benign GI strictures are another published use (Ann Gastroenterol, 2019).

Labeling changes over time. In 2023, the FDA granted a U.S. indication to one LAMS system, in 10 x 10 mm and 15 x 10 mm sizes, for gallbladder drainage in patients with acute cholecystitis at high surgical risk (FDA, DEN230019). Whether a use is on-label or off-label depends on the device, the size, the indication, the country, and the date.

Physician specialty societies describe off-label use of legally marketed devices as a normal part of medical practice, guided by medical judgment and published evidence (Alliance of Specialty Medicine). Not every published use rests on the same depth of evidence, though. In a legal review, the useful question is what the evidence showed for that use, in that patient, at that time.

Patients who need LAMS procedures are often very sick. Many have cancer, severe pancreatitis, or serious heart or lung disease. That context matters when an outcome is later reviewed.

Recognized LAMS complications in the published literature

The medical literature describes a known set of LAMS adverse events. They are described in systematic reviews, technology reviews, and pooled studies from many centers. The main ones are:

  • Misdeployment, where one or both flanges do not open in the intended place
  • Bleeding, either during the procedure or days to weeks later
  • Perforation or leak at the site of the new passage
  • Stent migration, where the stent moves out of position
  • Stent occlusion or dysfunction, from food, debris, or tissue
  • Infection, including infection of a drained collection
  • Buried stent, where tissue grows over a flange

Reported rates vary a great deal. They depend on the procedure, the patient group, the study design, and how each study defined an adverse event. A few pooled figures show the range:

ProcedureStudyWhat was reported
EUS-CDS with LAMSMeta-analysis, 21 studies, 1,438 patients (J Gastroenterol Hepatol, 2024)Overall adverse events 20.1% (early 10.6%, late 11.2%); stent dysfunction 10.5%; reintervention 12.1%
EUS-CDS with LAMSMeta-analysis, 7 studies, 284 patients (Surg Endosc, 2020)Post-procedure adverse events 5.2%
Walled-off necrosis drainageMeta-analysis, 30 studies, 1,524 patients (Endosc Int Open, 2020)With LAMS: bleeding 2.5%, perforation 0.5%, migration 5.9%, occlusion 3.8%; similar to plastic stents
Gallbladder drainageMeta-analysis comparing EUS-GBD with percutaneous drains (Gastrointest Endosc, 2024)Similar early adverse events; fewer delayed and overall adverse events with EUS-GBD

The two EUS-CDS meta-analyses measured different endpoints: post-procedure adverse events in one, and overall adverse events including later events in the other. Their figures are not directly comparable. Any rate needs to be read with the study's definitions, follow-up period, patient group, and the events it counted.

LAMS misdeployment and rescue

LAMS misdeployment is a well-documented adverse event. A 2023 systematic review described it as a relatively common event in EUS-guided drainage. It reported misdeployment rates of 5.8% for EUS-CDS, 3.4% for gallbladder drainage, and 2.0% for pancreatic fluid collection drainage (World J Gastroenterol, 2023).

The same review found that endoscopic rescue was possible in most cases: 86.8%, 80%, and 96.8% for those three procedures. Rescue options included placing a new stent over a wire through the tract already created, placing a second stent through the first, or repeating the drainage another way. Those figures describe published series. Applying them to an individual requires assessment of the procedure, the misdeployment pattern, the patient's condition, the recognition and response, and the clinical course.

For EUS-guided gastroenterostomy, a 16-center study from the United States and Europe reported misdeployment in 46 of 467 procedures (9.85%). Most were mild or moderate and were managed endoscopically, and about 11% needed surgery (Gastrointest Endosc, 2022). That study proposed a four-type classification based on which flange was misdeployed.

Updated EUS-GE misdeployment classification (2026)

In 2026, an updated classification of EUS-GE misdeployment was published in Digestive Endoscopy (Chavan, Devani, et al.). Dr. Devani is a co-author. The update expands the four types to six. Types II and III are now split by whether guidewire access is kept, because guidewire access affects the rescue options. Two types were added: Type V, where the stent deploys fully into the abdominal cavity, and Type T, where it passes through and through a loop of bowel.

The paper proposes a management framework for each type. In that framework, management depends on the misdeployment pattern, when it is recognized, the patient's condition, and the expertise available. The paper describes endoscopic rescue as fitting selected situations. It also describes circumstances, such as diffuse peritonitis, hemodynamic instability, or significant colonic injury with contamination, in which the authors suggest early surgical consultation or upfront surgery. For a legal review, the point is plain. Misdeployment is a named and classified event in the medical literature, with management options that differ by type and by patient. The paper's suggestions inform analysis; their application requires assessment of the individual circumstances.

In a legal review, the occurrence of a misdeployment is only the start of the question. What follows matters as much: how the event was recognized, what was done next, how the patient did, and how it was documented.

How a gastroenterology expert witness reviews a LAMS complication case

A known adverse event does not, by itself, show that care fell below accepted practice. These procedures carry real risk even when they are done well, and the literature says so. The review looks at the full clinical picture, not only the outcome.

In practice, a reviewing interventional endoscopist works through questions like these. They are review questions, not a mandatory checklist for every case:

  1. Indication. What problem was being treated, and what other options were reasonably available for this patient at that time?
  2. Patient condition. How sick was the patient before the procedure? What was their surgical risk?
  3. Consent. Were the recognized risks of the procedure discussed, and how was that recorded?
  4. The procedure record. What does the report, the imaging, and the timeline show about how the procedure went?
  5. Recognition and response. When the adverse event happened, when was it recognized, and what was done?
  6. Follow-up care. What happened in the hours and days after, and who was involved?
  7. Literature context. How does the event compare with what has been published for this procedure and this patient group?

Each answer is judged against the setting and the information available at the time, not with hindsight. Medicine also allows for more than one reasonable approach. Two experienced endoscopists may handle the same situation in different ways, and both can be acceptable.

The reviewer's own background matters. Recent procedure-specific experience can help explain technical decisions and how adverse events are recognized and managed. The relevance of an expert's qualifications depends on the particular opinion offered.

For more on what to look for, see Choosing a Gastroenterology Expert Witness for an Advanced Endoscopy Case. Related reviews include post-ERCP pancreatitis in malpractice litigation and standard of care in ERCP.

Frequently Asked Questions

What is a LAMS in gastroenterology?

A lumen-apposing metal stent is a short, wide, covered metal stent with flanges on both ends. It is placed under EUS guidance to join two structures and create a drainage path or bypass.

What are the most common LAMS complications?

Published studies describe misdeployment, bleeding, perforation, stent migration, stent occlusion, infection, and buried stent. Rates vary by procedure, patient group, and how each study defined an adverse event.

Is LAMS misdeployment a known risk?

Yes. It is described in systematic reviews as a relatively common adverse event in EUS-guided drainage. Published reviews report endoscopic rescue in most cases, though some patients need surgery. Those figures describe published series. Applying them to an individual requires assessment of the procedure, the misdeployment pattern, the patient's condition, the recognition and response, and the clinical course.

Is there a classification system for LAMS misdeployment?

Yes, for EUS-guided gastroenterostomy. A four-type system was published in 2022. An updated six-type system, published in Digestive Endoscopy in 2026, adds subtypes based on guidewire access and two new types. The paper proposes a management framework for each type, ranging from endoscopic rescue to surgery. The paper's suggestions inform analysis; their application requires assessment of the individual circumstances.

Is off-label use of LAMS common?

Yes. LAMS were first approved for pancreatic fluid collections. Published reviews describe several well-known off-label uses, including EUS-guided gastroenterostomy, EUS-CDS, EDGE, and short GI strictures. Since 2023, some devices and sizes also carry a U.S. indication for gallbladder drainage in high-risk patients. Specialty societies describe off-label use of legally marketed devices as a recognized part of medical practice.

Does a LAMS complication mean malpractice occurred?

Not by itself. A recognized adverse event can happen even when care is appropriate. Whether care met accepted practice depends on the full clinical picture, reviewed by a qualified expert.

Why use an interventional endoscopist as the expert?

LAMS procedures are done mostly by interventional endoscopists. Recent procedure-specific experience can help explain the indication, the technique, the known risks, and how adverse events are recognized and managed. The relevance of an expert's qualifications depends on the particular opinion offered.

What records help an expert review a LAMS case?

The procedure report and images, consent documents, pre-procedure notes and imaging, nursing and anesthesia records, and post-procedure notes through discharge. Any later procedures or surgery records are also useful.

About the author

Dr. Kalpit Devani, MD, FACP, FACG, FASGE.

Dr. Kalpit Devani, MD, FACP, FACG, FASGE, is a double board certified interventional gastroenterologist and Director of Endoscopy in Greenville, South Carolina. He performs more than 1,000 advanced procedures a year, including therapeutic EUS and EUS-guided drainage. He has published more than 30 peer-reviewed papers and given more than 75 national and international presentations. He is a co-author of the 2026 updated classification of stent misdeployment during EUS-guided gastroenterostomy, published in Digestive Endoscopy.

Dr. Devani provides defense-side case review and testimony in gastroenterology and advanced endoscopy matters. Retention by the defense does not change the analysis. Opinions remain independent and are based on the medical record, the clinical circumstances, and the standards prevailing when care occurred.

Reviewing a LAMS or EUS-guided drainage case? Contact Dr. Devani for a case review consultation.

References

  1. Li JS, Tang J, Fang J, Li ZS, Liu F. Adverse events in endoscopic ultrasound-guided choledochoduodenostomy with lumen-apposing metal stents: a systematic review and meta-analysis. J Gastroenterol Hepatol. 2024;39(9):1769-1779. doi:10.1111/jgh.16614. PubMed
  2. Krishnamoorthi R, Dasari CS, Thoguluva Chandrasekar V, et al. Effectiveness and safety of EUS-guided choledochoduodenostomy using lumen-apposing metal stents (LAMS): a systematic review and meta-analysis. Surg Endosc. 2020;34(7):2866-2877. doi:10.1007/s00464-020-07484-w. PubMed
  3. Chandrasekhara V, Barthet M, Deviere J, et al. Safety and efficacy of lumen-apposing metal stents versus plastic stents to treat walled-off pancreatic necrosis: systematic review and meta-analysis. Endosc Int Open. 2020;8(11):E1639-E1653. doi:10.1055/a-1243-0092. Journal
  4. Hayat U, Al Shabeeb R, Perez P, et al. Safety and adverse events of EUS-guided gallbladder drainage using lumen-apposing metal stents and percutaneous cholecystostomy tubes: a systematic review and meta-analysis. Gastrointest Endosc. 2024;99(3):444-448.e1. doi:10.1016/j.gie.2023.10.043. PubMed
  5. Armellini E, Metelli F, Anderloni A, et al. Lumen-apposing metal stent misdeployment in endoscopic ultrasound-guided drainages: a systematic review focusing on issues and rescue management. World J Gastroenterol. 2023;29(21):3341-3361. doi:10.3748/wjg.v29.i21.3341. Journal
  6. Ghandour B, Bejjani M, Irani SS, et al. Classification, outcomes, and management of misdeployed stents during EUS-guided gastroenterostomy. Gastrointest Endosc. 2022;95(1):80-89. doi:10.1016/j.gie.2021.07.023. PubMed
  7. Chavan R, Devani K, Sundaram S, Gandhi C, Rajput S. Updated Classification of EUS-Guided Gastroenterostomy Misdeployment. Dig Endosc. 2026;38(9):e70285. doi:10.1111/den.70285. Journal
  8. Law RJ, Chandrasekhara V, Bhatt A, et al. Lumen-apposing metal stents (with videos). Gastrointest Endosc. 2021;94(3):457-470. doi:10.1016/j.gie.2021.05.020. PubMed
  9. She YM, Ge N. Clinical application and follow-up of electrocautery-enhanced lumen-apposing metal stents for endoscopic ultrasonography-guided interventions. Ann Med. 2023. doi:10.1080/07853890.2023.2282748. Journal
  10. Larson B, Adler DG. Lumen-apposing metal stents for gastrointestinal luminal strictures: current use and future directions. Ann Gastroenterol. 2019;32(2):141-146. doi:10.20524/aog.2018.0337. PMC
  11. Alliance of Specialty Medicine. Physician-directed applications (off-label use) position statement, updated March 2017. Link

Dr. Kalpit Devani, MD, FACP, FACG, FASGE is a board-certified interventional gastroenterologist based in Greenville, South Carolina, specializing in diagnostic and therapeutic EUS, complex ERCP, and endoscopic suturing.

This article is general educational information for legal and medical professionals. It is not medical advice, legal advice, or an opinion on any specific case. It does not describe the care of any individual patient. Published rates come from the studies cited and may not apply to a given patient or setting. The views here are the author's own and do not represent any employer or institution.

Share: